Cell Therapy Conferences
Cell therapies are transforming the treatment landscape across oncology and autoimmunity, with 9 FDA-approved therapies to date, including landmark approvals for CAR-T, TIL, and TCR-engineered products. These therapies have demonstrated curative potential, particularly in hematologic malignancies, but now the field is rapidly expanding it’s footprint to target autoimmune diseases.
The industry is now entering a new era of next-generation cell therapy development—characterized by enhanced specificity, persistence, and safety—while simultaneously tackling the challenges of scalable, global manufacturing. From automated, decentralized production platforms to off-the-shelf allogeneic solutions, the focus is on delivering globally accessible, life-changing therapies that are robust, cost-effective, and clinically impactful.